NO20055001L - Nytt difenylazetidinon med forbedrede fysiologiske egenskaper, fremgangsmate for fremstilling derav, legemiddel inneholdende forbindelsen og anvendelse derav - Google Patents

Nytt difenylazetidinon med forbedrede fysiologiske egenskaper, fremgangsmate for fremstilling derav, legemiddel inneholdende forbindelsen og anvendelse derav

Info

Publication number
NO20055001L
NO20055001L NO20055001A NO20055001A NO20055001L NO 20055001 L NO20055001 L NO 20055001L NO 20055001 A NO20055001 A NO 20055001A NO 20055001 A NO20055001 A NO 20055001A NO 20055001 L NO20055001 L NO 20055001L
Authority
NO
Norway
Prior art keywords
preparation
new
diphenylazetidinone
drug
containing compound
Prior art date
Application number
NO20055001A
Other languages
English (en)
Norwegian (no)
Inventor
Heiner Glombik
Hubert Heuer
Werner Kramer
Wendelin Frick
Hans-Ludwig Schaefer
Andreas Lindenschmidt
Gerhard Jaehne
Stefanie Flohr
Eric Galia
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20055001L publication Critical patent/NO20055001L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
NO20055001A 2003-04-01 2005-10-27 Nytt difenylazetidinon med forbedrede fysiologiske egenskaper, fremgangsmate for fremstilling derav, legemiddel inneholdende forbindelsen og anvendelse derav NO20055001L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10314610A DE10314610A1 (de) 2003-04-01 2003-04-01 Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
PCT/EP2004/002690 WO2004087655A1 (de) 2003-04-01 2004-03-16 Neues diphenylazetidinon mit verbesserten physiologischen eigenschaften, verfahren zu dessen herstellung, diese verbindungen enthaltende arzneimittel und dessen verwendung

Publications (1)

Publication Number Publication Date
NO20055001L true NO20055001L (no) 2005-10-27

Family

ID=33103147

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055001A NO20055001L (no) 2003-04-01 2005-10-27 Nytt difenylazetidinon med forbedrede fysiologiske egenskaper, fremgangsmate for fremstilling derav, legemiddel inneholdende forbindelsen og anvendelse derav

Country Status (44)

Country Link
US (2) US7205290B2 (es)
EP (2) EP1862455B1 (es)
JP (1) JP2006522040A (es)
KR (1) KR20050119180A (es)
CN (2) CN100361970C (es)
AR (1) AR043783A1 (es)
AT (2) ATE386020T1 (es)
AU (1) AU2004226287B2 (es)
BR (1) BRPI0408920A (es)
CA (1) CA2520689A1 (es)
CL (1) CL43489B (es)
CR (1) CR7995A (es)
CY (2) CY1107398T1 (es)
DE (3) DE10314610A1 (es)
DK (2) DK1862455T3 (es)
EC (1) ECSP056071A (es)
ES (2) ES2322876T3 (es)
GT (1) GT200400058A (es)
HK (1) HK1087697A1 (es)
HN (1) HN2004000109A (es)
HR (1) HRP20050870A2 (es)
JO (1) JO2493B1 (es)
MA (1) MA27753A1 (es)
ME (1) MEP41408A (es)
MX (1) MXPA05010128A (es)
MY (1) MY136269A (es)
NI (1) NI200500164A (es)
NO (1) NO20055001L (es)
NZ (1) NZ542751A (es)
PA (1) PA8599401A1 (es)
PE (1) PE20050011A1 (es)
PL (2) PL1862455T3 (es)
PT (2) PT1862455E (es)
RS (1) RS51146B (es)
RU (1) RU2334737C2 (es)
SA (1) SA04250154B1 (es)
SI (2) SI1613589T1 (es)
SV (1) SV2004001756A (es)
TN (1) TNSN05244A1 (es)
TW (1) TW200504009A (es)
UA (1) UA80754C2 (es)
UY (1) UY28253A1 (es)
WO (1) WO2004087655A1 (es)
ZA (1) ZA200506708B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277890T3 (es) * 2000-12-21 2007-08-01 Sanofi-Aventis Deutschland Gmbh Nuevas difenilazetidinonas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para el tratamiento de trastornos del metabolismo de lipidos.
KR20080021082A (ko) 2005-06-20 2008-03-06 쉐링 코포레이션 히스타민 ｈ3 길항제로서 유용한 피페리딘 유도체
US7067689B1 (en) 2005-07-08 2006-06-27 Microbia, Inc. Process for production of pentahydroxyhexylcarbamoyl alkanoic acids
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
DE102007029612A1 (de) * 2007-06-27 2009-01-08 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Pentahydroxyhexylcarbamoylundekan- säurebenzylester
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2009100258A1 (en) * 2008-02-05 2009-08-13 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical solid state forms
DE102008059772A1 (de) 2008-12-01 2010-06-02 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung eines Diphenylazetidinons
WO2009112203A1 (de) * 2008-03-14 2009-09-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur herstellung eines diphenylazetidinons
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10426480B2 (en) * 2015-04-29 2019-10-01 Covidien Lp Cutting ring assembly with rigid cutting member

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5756740A (en) * 1992-04-08 1998-05-26 Eastman Kodak Company Process for the preparation of binary sensitizing dyes
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
CN1264384A (zh) 1997-07-16 2000-08-23 诺沃挪第克公司 稠合1,2,4-噻二嗪衍生物及其制备方法和用途
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
EP1063235B1 (en) 1998-03-12 2004-05-12 Teijin Limited Benzofurylpyrone derivatives
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
PL202367B1 (pl) 1998-12-07 2009-06-30 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
WO2000064876A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
DE60035682T2 (de) 1999-04-28 2008-04-30 Sanofi-Aventis Deutschland Gmbh Di-aryl-säurederivate als ppar rezeptor liganden
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
EP1204654B1 (en) 1999-07-29 2003-07-23 Eli Lilly And Company Benzofurylpiperazines: 5-ht2c serotonin receptor agonists
AU774071B2 (en) * 1999-09-01 2004-06-17 Sanofi-Aventis Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
WO2001062266A2 (en) 2000-02-25 2001-08-30 Novo Nordisk A/S Use of dpp-iv inhibitors for the treatment of diabetes
CN1430603A (zh) 2000-04-28 2003-07-16 旭化成株式会社 新型双环化合物
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
HUP0004741A2 (hu) 2000-11-28 2002-12-28 Sanofi-Synthelabo Kémiai eljárás tiazolszármazékok előállítására és új intermedier
ES2277890T3 (es) * 2000-12-21 2007-08-01 Sanofi-Aventis Deutschland Gmbh Nuevas difenilazetidinonas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para el tratamiento de trastornos del metabolismo de lipidos.
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6884812B2 (en) * 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
CA2458210C (en) * 2001-08-31 2011-09-20 Aventis Pharma Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar-activators
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
DE502004006195D1 (de) 2008-03-27
ZA200506708B (en) 2007-01-31
RS20050719A (en) 2008-04-04
AU2004226287B2 (en) 2010-03-18
PT1613589E (pt) 2008-03-27
MY136269A (en) 2008-09-30
PL1613589T3 (pl) 2008-07-31
SI1613589T1 (sl) 2008-06-30
EP1613589B1 (de) 2008-02-13
US20050020563A1 (en) 2005-01-27
PE20050011A1 (es) 2005-02-28
PT1862455E (pt) 2009-04-23
ES2298731T3 (es) 2008-05-16
US7772429B2 (en) 2010-08-10
ECSP056071A (es) 2006-01-27
RU2005133631A (ru) 2006-03-10
EP1613589A1 (de) 2006-01-11
NI200500164A (es) 2006-01-11
CN100361970C (zh) 2008-01-16
ATE423766T1 (de) 2009-03-15
US7205290B2 (en) 2007-04-17
CA2520689A1 (en) 2004-10-14
HK1087697A1 (en) 2006-10-20
ATE386020T1 (de) 2008-03-15
TW200504009A (en) 2005-02-01
HN2004000109A (es) 2008-02-21
RU2334737C2 (ru) 2008-09-27
ES2322876T3 (es) 2009-06-30
GT200400058A (es) 2004-11-10
TNSN05244A1 (en) 2007-06-11
EP1862455B1 (de) 2009-02-25
PA8599401A1 (es) 2004-10-08
EP1862455A3 (de) 2007-12-12
SA04250154B1 (ar) 2007-10-29
WO2004087655A1 (de) 2004-10-14
SV2004001756A (es) 2004-11-18
CY1107398T1 (el) 2012-12-19
MEP41408A (en) 2011-02-10
BRPI0408920A (pt) 2006-03-28
AR043783A1 (es) 2005-08-10
CN1768034A (zh) 2006-05-03
CL43489B (es) 2005-01-21
RS51146B (sr) 2010-10-31
MA27753A1 (fr) 2006-02-01
DK1613589T3 (da) 2008-06-09
SI1862455T1 (sl) 2009-06-30
CN101139306A (zh) 2008-03-12
CY1109055T1 (el) 2014-07-02
JP2006522040A (ja) 2006-09-28
DK1862455T3 (da) 2009-06-02
HRP20050870A2 (en) 2006-10-31
KR20050119180A (ko) 2005-12-20
AU2004226287A1 (en) 2004-10-14
MXPA05010128A (es) 2005-11-16
UY28253A1 (es) 2004-11-08
DE10314610A1 (de) 2004-11-04
PL1862455T3 (pl) 2009-07-31
CR7995A (es) 2006-09-22
EP1862455A2 (de) 2007-12-05
NZ542751A (en) 2007-05-31
DE502004009059D1 (de) 2009-04-09
JO2493B1 (en) 2009-10-05
US20070197498A1 (en) 2007-08-23
UA80754C2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
NO20055001L (no) Nytt difenylazetidinon med forbedrede fysiologiske egenskaper, fremgangsmate for fremstilling derav, legemiddel inneholdende forbindelsen og anvendelse derav
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
MY142830A (en) Propionic acid derivatives useful in the treatment of lipid disorders
NO20065904L (no) Terapeutiske forbindelser
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
UA66852C2 (uk) Похідні та аналоги 3-арилпропіонової кислоти, спосіб їх отримання, фармацевтична композиція (варіанти) та спосіб профілактики та/або лікування асоційованих з резистентністю до інсуліну клінічних станів
NO20054852L (no) GFAT inhibitorer
UA84156C2 (ru) Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer
RS20060015A (en) Substituted thiazole- benzoisothiazole dioxide derivatives, method for the production thereof and use of the same
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
NO20053809L (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
NO20073176L (no) Nye medikamenter for behandling av luftveissykdommer
NO20063619L (no) Diarylmetylpiperazinderivater, fremstilling og anvendelse derav
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
NO20054168L (no) Substituerte 3-(benzoylureido)-tiofenderivater, fremgangsmate for fremstilling og anvendelse derav
NO20063860L (no) 7-fenylamino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav samt deres anvendelse som legemidler
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
NO20054389L (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
WO2007104933A8 (en) Chemical compounds
NO20053805L (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
EP1666472A4 (en) PHENYL ACETIC ACID DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF
NO20045353L (no) Orto-substituerte benzosyrederivater for behandling av insulinresistens

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application